Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF) (2018 - 2025)

Zevra Therapeutics' Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $362000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 78.03% year-over-year to $362000.0; the TTM value through Dec 2025 reached $4.1 million, down 36.55%, while the annual FY2025 figure was $4.1 million, 36.55% down from the prior year.
  • Depreciation & Amortization (CF) reached $362000.0 in Q4 2025 per ZVRA's latest filing, down from $392000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.7 million in Q2 2025 to a low of $62000.0 in Q3 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $632500.0, with a median of $331000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 84.42% in 2023, then soared 2508.06% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $64000.0 in 2021, then surged by 368.75% to $300000.0 in 2022, then surged by 162.33% to $787000.0 in 2023, then skyrocketed by 109.4% to $1.6 million in 2024, then tumbled by 78.03% to $362000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Depreciation & Amortization (CF) are $362000.0 (Q4 2025), $392000.0 (Q3 2025), and $1.7 million (Q2 2025).